Saturday, March 2, 2024

Just Like PhRMA In West Texas, AZ Just Lost In Del. Federal Court…


Now pharma -- as an industry -- is 0-2, on these strike suits against the new federal drug price negotiation rules.

A loss in ruby red West Texas last month (suffered by PhRMA itself) has now been followed up by a much broader loss in the Delaware federal courts.

And this time, AstraZeneca was the defeated multinational. You may read the quite sensible opinion, here -- and the punchline:

. . .Because AstraZeneca does not have Article III standing to challenge the lawfulness of the guidance and because it has not identified a property interest protected by the Constitution that is put in jeopardy by the Program, I will deny AstraZeneca's motion and grant the Government's motion. . . .


Onward.

नमस्ते

No comments: